Premium
Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA ‐mutated prostate cancers
Author(s) -
Humeniuk Michael S.,
Zhang Tian,
Armstrong Andrew J.
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30806
Subject(s) - medicine , chemotherapy , dna damage repair , dna repair , prostate cancer , prostate , oncology , cancer research , brca mutation , dna damage , brca2 protein , mutation , dna , cancer , genetics , germline mutation , gene , biology , ovarian cancer
The report in this issue by Pomerantz and colleagues demonstrates that men with metastatic prostate cancer harboring germline BRCA2 mutations are strongly associated with a prostate‐specific antigen response ≥50% during treatment with a platinum agent. However, more work will be required to classify other men who might benefit from platinum agents. See also pages 3532‐9.